EUVIMEDOpdag EUVIMED
Crossref

A case of lenacapavir use for preventing mother-to-child HIV transmission

Victor Hémar iD, Stéphane Bouchet, Emmanuel Ribeiro, Perrine Prier, Christophe Elleau, Caroline Solas iD, Alexandre Destere iD, Mojgan Hessamfar, Camille Tumiotto, Fabrice Bonnet

Journal of Antimicrobial Chemotherapy · 2024-12-02 · 79 (12) · 3354-3355

DOI: 10.1093/jac/dkae348 ↗

At a glance

Journal article in Journal of Antimicrobial Chemotherapy, published online on 2024-09-30. Written by Victor Hémar and 9 co-authors. Institution: CHU de Bordeaux, Service de Médecine Interne et Maladies Infectieuses, Bordeaux, France. Cited 7 times so far (Crossref); 4 references.

AbstractBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Lenacapavir, a pioneering HIV capsid inhibitor approved for HIV treatment, is used in conjunction with other antiretroviral therapies (ARTs) in multidrug-resistant HIV infections and has shown efficacy in treatment-naive patients.1,2 Administered subcutaneously every 6 months, it represents a long-acting treatment option. In women with HIV who exhibit poor adherence to oral ART during pregnancy, the prevention of mother-to-child transmission (MTCT) poses major challenges. Injectable, long-acting treatments may be beneficial in these cases. However, data on the use of such treatments during pregnancy are limited, as pregnancy is typically an exclusion criterion in development trials, despite the absence of evidence for teratogenic effects in animal models.2 We present what we believe to be the first reported case of lenacapavir use in preventing MTCT in a 31-year-old woman. Diagnosed with HIV-1 in 2012 in Côte d’Ivoire at age 21, she has not developed any acquired immunodeficiency syndrome-related illnesses despite a nadir CD4 count of 1/mm3. She experienced poor adherence to various ART combinations, leading to multiple virological failures and limited immune reconstitution (maximum CD4 count of 329/mm3 in 2020). During her first pregnancy in 2020 in France, MTCT was prevented despite high viral replication. She underwent a preventive caesarean section, received peripartum ZDV infusion and her newborn was given prophylactic ART. Due to ongoing non-adherence to oral ART, she commenced an injectable long-acting regimen with cabotegravir + RPV in November 2022. Despite no initial resistance mutations to non-nucleoside reverse transcriptase inhibitors or integrase inhibitors, she developed virological failure due to rapid acquisition of resistance mutations. A new oral ART regimen of TDF + FTC + DRV/RTV was initiated in February 2023. In June 2023, at 12 weeks of pregnancy (WP), the patient was found to be pregnant and her HIV-1 viral load (VL) was 52 000 copies/mL. To improve her adherence to oral ART, supervised medication intake by a nurse was initiated at 13 WP. Figure 1 shows the changes in VL during the pregnancy. By 27 WP, the VL only slightly decreased to 49 600 copies/mL due to refusal of oral treatment. Consequently, a multidisciplinary council meeting approved the introduction of a triple injectable ART regimen including lenacapavir, enfuvirtide and ibalizumab. At 27 WP, she received a SC injection of lenacapavir (928 mg on Day 0) with a supervised oral lead-in phase (600 mg on Days 0 and 1, and 300 mg on Day 7). By 28 WP, the VL had reduced to 542 copies/mL, and the ART regimen was supplemented with IV ibalizumab every 2 weeks and SC enfuvirtide twice daily. Despite this regimen and proper dosing of lenacapavir (23.95 µg/L), the VL increased to 4logs by 32 WP. The RNA resistance genotype indicated an N74D mutation conferring resistance to lenacapavir, which emerged just 5 weeks after injection. Evolution of HIV-1 VL across WP, correlated with antiretroviral concentration and resistance. 3TC, lamivudine; ABC, abacavir; DRV/r, darunavir/ritonavir; FTC, emtricitabine; INSTI, integrase strand transfer inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; SC, subcutaneous; TDF, tenofovir disoproxil. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC. Due to the high VL, a planned caesarean section was performed at 36 WP, accompanied by ZDV infusion in the mother. After delivery, ZDV + 3TC + LPV/RTV was administered to the newborn for the first month, and breastfeeding was avoided. At birth, and at 1, 3 and 6 months, the newborn’s HIV RNA levels were undetectable. The lenacapavir level in the newborn at 3 days after birth was 30.60 µg/L, indicating transplacental transfer, while subsequent measurements at 1, 3 and 6 months showed levels below 5 ng/mL. Preclinical studies in rats and rabbits revealed no significant toxic effects on embryo–fetal or pre/postnatal development even at high doses.2 Although lenacapavir strongly binds to blood proteins (>98%) and has a high molecular weight (>500 Da), suggesting minimal transplacental transfer, its detection in nursing pups indicates potential transfer either via blood or milk, though the exact pathway remains unclear.2 In this case, the presence of lenacapavir in the newborn’s blood confirmed transplacental transfer. After 1 month, levels of lenacapavir fell

Authors and institutions

  • CHU de Bordeaux, Service de Médecine Interne et Maladies Infectieuses, Bordeaux, France.
  • CHU de Bordeaux, Laboratoire de Pharmacologie, Bordeaux, France.
  • CHU de Bordeaux, Service de Médecine Interne et Immunologie Clinique, Bordeaux, France.
  • CHU de Bordeaux, Service de Gynécologie-Obstétrique, Bordeaux, France.
  • CHU de Bordeaux, Service de Pédiatrie-Néonatologie, Bordeaux, France.
  • APHM, Hôpital de La Timone, Laboratoire de Pharmacocinétique et de Toxicologie, Unité des Virus Emergents (UVE: Aix-Marseille Univ IRD 190-Inserm 1207), Marseille, France.

ORCID profiles: Victor Hémar, Caroline Solas, Alexandre Destere

Cite

APA

Hémar, V., Bouchet, S., Ribeiro, E., Prier, P., Elleau, C., Solas, C., Destere, A., Hessamfar, M., Tumiotto, C., & Bonnet, F. (2024). A case of lenacapavir use for preventing mother-to-child HIV transmission. Journal of Antimicrobial Chemotherapy, 79(12), 3354-3355. https://doi.org/10.1093/jac/dkae348

Vancouver

Hémar V, Bouchet S, Ribeiro E, Prier P, Elleau C, Solas C, et al. A case of lenacapavir use for preventing mother-to-child HIV transmission. Journal of Antimicrobial Chemotherapy. 2024;79(12):3354-3355. doi:10.1093/jac/dkae348

BibTeX
@article{Hmar2024,
  author = {Hémar, Victor and Bouchet, Stéphane and Ribeiro, Emmanuel and Prier, Perrine and Elleau, Christophe and Solas, Caroline and Destere, Alexandre and Hessamfar, Mojgan and Tumiotto, Camille and Bonnet, Fabrice},
  title = {A case of lenacapavir use for preventing mother-to-child HIV transmission},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  volume = {79},
  number = {12},
  pages = {3354--3355},
  doi = {10.1093/jac/dkae348}
}
Start for free →